As part of its ongoing effort to implement IRA changes to the Medicare Part D program, CMS issued Medicare Drug Price Negotiation Program Draft Guidance on May 3, requesting feedback and comments from interested stakeholders.
The EACH Coalition submitted a group comment letter advocating for increased opportunities for patient engagement and urging for patient protections against decreased access to needed medications.
The letter was signed by 26 organizations. It provided CMS with feedback on the listening sessions held for the first round of negotiated drugs in October of 2023, outlined specific recommendations for future listening sessions, and urged for protections against increased utilization management in plans.